Recombinant Capital Presents

ALLICENSE 2002
BECOMING THE PARTNER OF CHOICE

April 9 & 10, 2002
Fairmont Hotel, San Francisco, CA

Program Agenda (As of: April 3, 2002)

All Speakers confirmed

Tuesday, April 9 8:00 – 8:30 Welcoming Remarks & Conference Overview: Alliances Move to Center Stage · Mark G. Edwards, Managing Director, Recombinant Capital 8:30 – 9:00 Keynote Presentation: Becoming Biotech’s Partner of Choice · David P. Holveck, Company Group Chairman, Johnson & Johnson 9:00 – 9:30 Using Alliances in Product Life Cycle Management · Kenneth Weg, Chairman, Clearview Projects and former President, Worldwide Medicines Group, Bristol-Myers Squibb Morning Break 9:30 – 10:00 10:00 – 12:00 Session 1: Best Practices in Alliance Negotiation and Management · Session Chair: David E. Thompson, Vice President, Corporate Strategy & Business Development, Eli Lilly · Dr. Thomas Hofstaetter, Senior Vice President, Corporate Development, Aventis · Dr. Julie A. Olson, Vice President, Global Licensing, Pfizer · Barbara Yanni, Chief Licensing Officer, Merck & Co. Luncheon 12:00 – 1:00 1:00 – 3:00 Session 2: Alliances Across the Corporate Life Cycle · Session Chair: James M. Gower, Chief Executive Officer, Rigel Pharmaceuticals · Dr. Laurence Jay Korn, Chief Executive Officer, Protein Design Labs · Dr. Ivan Lieberburg, Executive Vice President & Chief Scientific Officer, Elan Corporation · Robert Whitehead, Senior Vice President & Chief Business Officer, ZymoGenetics Afternoon Break 3:00 - 3:30 3:30 – 5:30 Session 3: Deal-Making and Relationship Management as a Partner of Choice · Session Chair: Tamar Howson, Senior Vice President, Corporate and Business Development, Bristol-Myers Squibb · Keith Dionne, Vice President & General Manager of Techhnology Business, Millennium Pharmaceutical · James J. Dolan, Vice President, Licensing & Business Development, Purdue Pharma · Scott Foraker, Vice President, Licensing, Amgen Allicense 2002 Breakthrough Awards Dinner

Wednesday, April 10 8:00 – 8:30 Integrating Alliances Across Pharma’s Pipeline · Dr. Göran Ando, Executive Vice President & President, Research & Development, Pharmacia 8:30 – 9:00 Redefining How Medicines are Discovered · Dr. Wendell Wierenga, Chief Executive Officer, Syrrx 9:00 – 9:30 Leveraging Platform Technologies · David Slack, Vice President of Business Development, ISIS Pharmaceuticals Morning Break 9:30 – 10:00 10:00 – 12:00 Session 4: Best Practices in Alliance Negotiation and Management – Part 2 · Session Chair: Dr. Thomas A. Picone, Vice President, Global Licensing, Pharmacia · Dr. Mark L. Lee, Vice President Worldwide Licensing, Wyeth · R. Christopher Seaton, Senior Vice President, Global Licensing, Bayer Corporation · Paul J. Sekhri, Senior Vice President, Worldwide Business Development & Licensing, Novartis Pharmaceuticals Luncheon 12:00 – 1:00 1:00 – 2:30 Session 5: North-South Alliances: Obtaining R&D Funding for Third World Diseases · Session Chair: Dr. Maria Freire, Chief Executive Officer, Global Alliance for TB Drug Development · Dr. Christopher Hentschel, Chief Executive Officer, Medicines for Malaria Venture · Maria Marmarinos, Executive Vice President, Business Development, Sequella Afternoon Break 2:30 – 3:00 3:00 – 4:30 Session 6: The Answer: Business Development. What Was the Question? · Session Chair: Jack M. Anthony, Vice President, Business Development, FibroGen · Mark G. Edwards, Managing Director, Recombinant Capital · Arlene Morris, President & CEO, Clearview Projects · Dr. Thomas A. Picone, Vice President, Global Licensing, Pharmacia Cocktail Reception 4:30 - 6:00